Oral mosapride can provide additional anti-emetic efficacy following total joint arthroplasty under general anesthesia: a randomized, double-blinded clinical trial

Table 5 The requirement of rescue treatment and postoperative VAS pain score

	Control (n = 80)	Dexa (n = 82)	Mosa+Dexa (n = 78)	p*	p1^†	p2^†	p3^†
Metoclopramide
Number	17 (21.3%)	8 (9.8%)	2 (2.6%)	0.001	0.043	< 0.001	0.060
Mean dose (mg)	2.88 (40)	1.10 (20)	0.26 (10)	0.002	0.044	0.002	0.496
VAS-rest 24 h	2.66 ± 0.72	2.45 ± 0.91	2.59 ± 0.82	0.333
VAS-rest 48 h	2.16 ± 0.99	2.03 ± 0.73	2.15 ± 0.71	0.551
Pethidine
Number	30 (37.5%)	19 (23.2%)	21 (26.9%)	0.116
Mean dose (mg)	20 (100)	17.38 (50)	16.99 (100)	0.486

Data presented as number of patients (percentage), mean (range) or mean ± standard deviation. Dexa dexamethasone; Mosa mosapride
* Uncorrected p values (for the three-way comparison)
^† Bonferroni-corrected p values: p1, Control vs Dexa; p2, Control vs. Mosa+Dexa; p3, Dexa vs. Mosa-Dexa. The corrected significance threshold was 0.016

ISSN: 1471-2253